Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) FCF Margin (2023 - 2025)

Kura Oncology (KURA) has disclosed FCF Margin for 3 consecutive years, with 649.87% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 6733945.0% to 649.87% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 104.76% through Dec 2025, up 816238.0% year-over-year, with the annual reading at 104.76% for FY2025, 35316.0% down from the prior year.
  • FCF Margin for Q4 2025 was 649.87% at Kura Oncology, up from 389.9% in the prior quarter.
  • The five-year high for FCF Margin was 12293.47% in Q1 2024, with the low at 66689.58% in Q4 2024.
  • Average FCF Margin over 3 years is 117.69%, with a median of 6917.02% recorded in 2023.
  • The sharpest move saw FCF Margin plummeted -7540125bps in 2024, then soared 6733945bps in 2025.
  • Over 3 years, FCF Margin stood at 8711.68% in 2023, then plummeted by -866bps to 66689.58% in 2024, then soared by 101bps to 649.87% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 649.87%, 389.9%, and 197.77% for Q4 2025, Q3 2025, and Q2 2025 respectively.